Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). This study was undertaken to evaluate the risk of major adverse cardiovascular events (MACE) in patients with RA receiving tofacitinib. METHODS: Data were pooled from patients with moderately to severely...

Descripción completa

Detalles Bibliográficos
Autores principales: Charles‐Schoeman, Christina, DeMasi, Ryan, Valdez, Hernan, Soma, Koshika, Hwang, Lie‐Ju, Boy, Mary G., Biswas, Pinaki, McInnes, Iain B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754249/
https://www.ncbi.nlm.nih.gov/pubmed/31385441
http://dx.doi.org/10.1002/art.40911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754249/
https://www.ncbi.nlm.nih.gov/pubmed/31385441
http://dx.doi.org/10.1002/art.40911

Ejemplares similares